← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #841 OF 1,000 MOST-CITED

Ensuring compliance with plan and protocol

FDA cited this observation 18 times across 17 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Bioresearch Monitoring18
BY FISCAL YEAR
FY20261
FY20252
FY20242
FY20231
FY20221
FY20203
FY20192
FY20182
FY20174

How FDA worded it — real examples

Failure to ensure that an investigation was conducted in accordance with the general investigational plan and protocols as specified in the IND.

Filipa Lynce, M.D. · Boston, Massachusetts · Bioresearch Monitoring · 2025-10-21

Failure to ensure that an investigation was conducted in accordance with the general investigational plan and protocols as specified in the IND.

Boehringer Ingelheim Pharmaceuticals, Inc. · Ridgefield, Connecticut · Bioresearch Monitoring · 2025-09-11

Failure to ensure that an investigation was conducted in accordance with the general investigational plan and protocols as specified in the IND.

Shaji K. Kumar, M.D. · Rochester, Minnesota · Bioresearch Monitoring · 2025-06-20

Failure to ensure that an investigation was conducted in accordance with the general investigational plan and protocols as specified in the IND.

Liana Apostolova, M.D. · Indianapolis, Indiana · Bioresearch Monitoring · 2024-04-18

Failure to ensure that an investigation was conducted in accordance with the general investigational plan and protocols as specified in the IND.

GE Healthcare Inc. · Arlington Heights, Illinois · Bioresearch Monitoring · 2024-03-08

Failure to ensure that an investigation was conducted in accordance with the general investigational plan and protocols as specified in the IND.

Anish S. Shah, M.D. · Santa Rosa, California · Bioresearch Monitoring · 2022-12-16

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

GCP discipline

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →